An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/2/2019 |
| Start Date: | March 1, 2018 |
| End Date: | July 5, 2023 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
The purpose of this study is to determine whether BMS-986258 both by itself and in
combination with Nivolumab is safe and tolerable in the treatment of advanced malignant
tumors
combination with Nivolumab is safe and tolerable in the treatment of advanced malignant
tumors
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,
recurrent, and/or unresectable) with measurable disease and have at least 1 lesion
accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Participants must have received, and then progressed, relapsed, or been intolerant to,
at least 1 standard treatment regimen in the advanced or metastatic setting according
to solid tumor histologies
Exclusion Criteria:
- Participants with active, known or suspected autoimmune disease
- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
anti-cancer therapy and initiation of study therapy
- Participants with other active malignancy requiring concurrent intervention
- Participants with active, known or suspected autoimmune disease
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Click here to add this to my saved trials